Understand the source comparison
Peptide Research News September 2026 Roundup: Metabolic, Cognitive & Immune Comparison
The following table summarizes the three major peptide categories that dominated September 2026 research developments, their mechanisms, clinical milestones, and research implications. Dual-Receptor Metabolic Agonists Survodutide, Mazdutide GLP-1/glucagon co-a
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table summarizes the three major peptide categories that dominated September 2026 research developments, their mechanisms, clinical milestones, and research implications.
- Dual-Receptor Metabolic Agonists
- Survodutide, Mazdutide
- GLP-1/glucagon co-agonism activates parallel metabolic pathways
- Phase 3 NASH trial: 18.7% weight reduction, 47% histological resolution
- Superior to single-receptor GLP-1 agonists in head-to-head trials
- Metabolic syndrome, hepatic steatosis, energy expenditure pathway studies
- Cognitive Enhancement Peptides
- Dihexa, Cerebrolysin, P21
- HGF mimetic synaptogenesis (dihexa), neurotrophic factor delivery (cerebrolysin)
- Phase 3 MCI trial initiated; post-stroke cognition trial completed
- 3.2-point ADAS-Cog improvement (dihexa); 58% functional independence post-stroke (cerebrolysin)
- Neuroplasticity research, synaptic density restoration, cognitive aging models
- Thymic & Immune Regeneration
- Thymalin, KPV
- Thymopoietin restoration (thymalin), NF-κB inhibition (KPV)
- First human thymic regeneration data published; Phase 2 IBD remission achieved
- Naive T-cell increase from 8.2% to 16.7%; 68% UC remission (KPV)
- Immune senescence reversal, inflammaging studies, autoimmune disease models